Abnormalities of p53 Protein Expression in Cutaneous Disorders

Archives of Dermatology

Volumn 130, Issue 2, 1994, Pages 225-232

  Mcnutt, N Scott ^a   Saenz Santamaria, Carmen ^a   Volkenandt, Matthias ^b   Shea, Christopher R ^a   Albino, Anthony P ^c  

^a Departments of Dermatology   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CELL CYCLE S PHASE; DNA DAMAGE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN SYNTHESIS; REVIEW; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

GENE EXPRESSION; GENES, P53; HUMAN; KERATOACANTHOMA; POROKERATOSIS; SKIN DISEASES; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION FACTORS;

EID: 0028057733     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1994.01690020091015     Document Type: Article

References (96)

1. 1. Kerschmann RL, McCalmont TH, LeBoit PE. p53 Oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol. 1994; 130: 181-186.
2. 2. Magee JW, McCalmont TH, LeBoit PE. Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol. 1994; 130: 187-190.
3. 3. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol. 1986; 6: 1379-1385.
4. 4. Isobe M, Emanuel BS, Givoli D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986; 320: 84-85.
5. 5. Yokota A, Wad M, Shimosato Y, Terada M, Sugimura T. Loss of heterozygosity on chromosomes 3,13,17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 1987; 84: 9252-9256.
6. 6. Viallet J, Minna JD. Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Respir Cell Mol Biol. 1990; 2: 225-232.
7. 7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science. 1991; 253: 49-53.
8. 8. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342: 705-708.
9. 9. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. Am J Pathol. 1992; 140: 145-153.
10. 10. Harris AL. Mutant p53: the commonest genetic abnormality in human cancer. J Pathol. 1990; 162: 5-6.
11. 11. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science. 1990; 249: 1046-1049.
12. 12. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990; 249: 1049-049-1051.
13. 13. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991; 252: 1708-1711.
14. 14. EI-Deiry WS, Kern SE, Pientenpol J, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1992; 1: 45-49.
15. 15. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol. 1992; 12: 2866-2871.
16. 16. Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A. 1993; 90: 3319-3323.
17. 17. Stenger JE, Mayr GA, Mann K, Tegtmeyer P. Formation of stable p53 homotetramers and multiples of tetramers. Mol Carcinog. 1992; 5: 102-106.
18. 18. Mercer WE, Baserga R. Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes. Exp Cell Res. 1985; 160: 31-46.
19. 19. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990; 249: 912-915.
20. 20. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell. 1989; 57: 1083-1093.
21. 21. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature. 1991; 351: 453-456.
22. 22. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi Kimhi O, Oren M. Wild-type p53 can inhibit oncogenemediated focus formation. Proc Natl Acad Sci U S A. 1989; 86: 8763-8767.
23. 23. Vogelstein B, Kinzler KW. p53 Function and dysfunction. Cell. 1992; 70: 523-526.
24. 24. Li FP, Fraumeni JF. Prospective study of a family cancer syndrome. JAMA. 1982; 247: 2692-2694.
25. 25. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-1238.
26. 26. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 1992; 356: 215-221.
27. 27. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990; 348: 747-749.
28. 28. Hao M, Finlay CA, Lozano G. A functionally inactive p53 Li-Fraumeni syndrome mutant. Oncogene. 1993; 8: 299-306.
29. 29. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsp70-p53 complex with an altered half-life. Mol Cell Biol. 1988; 8: 531-539.
30. 30. Oren M, Maltzman W, Levine AJ. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol. 1981; 1: 101-110.
31. 31. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol. 1983; 3: 2143-2150.
32. 32. Rogel A, Popliker M, Webb CG, Oren M. p53 Cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol. 1985; 5: 2851-2855.
33. 33. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51: 6304-6311.
34. 34. Longanzo F Jr, Nabeya Y, Maslak P, Albino AP. Stabilization of p53 protein is a critical response to UV radiation in human melanocytes: implications for melanoma development. Mol Cell Differ. In press.
35. 35. Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degredation rate of p53 in human keratinocytes. J Virol. 1992; 66: 6237-6241.
36. 36. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry. J Pathol. 1992; 166: 329-330.
37. 37. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990; 335: 675-679.
38. 38. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem. 1986; 159: 529-534.
39. 39. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Meth. 1992; 151: 237-244.
40. 40. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J. 1990; 9: 1595-1602.
41. 41. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci. 1992; 101: 183-189.
42. 42. Urano Y, Oura H, Sakaki A, et al. Immunohistochemical analysis of p53 expression in human skin tumors. J Dermatol Sci. 1992; 4: 69-75.
43. 43. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A, Oren M. Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature. 1986; 320: 182-185.
44. 44. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248: 76-79.
45. 45. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 188 promotes the degradation of p53. Cell. 1990; 63: 1129-1136.36.
46. 46. Lane DP, Crawford LV. T-antigen is bound to a host protein in SV40 transformed cells. Nature. 1979; 278: 261-263.
47. 47. Slater SD, McGrath JA, Hobbs C, Eady RAJ, McKee PH. Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive dystrophic epidermolysis bullosa. Histopathology. 1992; 1992; 20: 237-241.
48. 48. Van den Berg FM, Baas IO, Polak MM. Offerhaus JA. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol. 1993; 142: 381-385.
49. 49. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res. 1991; 4: 35-40. 1991;4:35-40.
50. 50. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res. 1991; 51: 5976-5979.5976-5979.
51. 51. Albino AP, Shea CR, McNutt NS. Oncogenes in melanoma. J Dermatol. 1992; 19: 853-867.
52. 52. Hall PA, McKee PH, Du Menage H, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 1993; 8: 203-207.
53. 53. Akslen LA, Morkve O. Expression of p53 protein in cutaneous melanoma. Int JCancer. 1992; 52: 13-166.
54. 54. Barnes DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet. 1992; 340: 259-263.
55. 55. Ziegler A, Leffell DJ, Kunala S, et al. Mutationhotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A. 1993; 90: 4216-4220.
56. 56. Campbell C, Quinn AG, Angus B, Rees JL. The relation between p53 mutation and p53 Immunostaining in non-melanoma skin cancer. Br J Dermatol. 1993; 129: 235-241.
57. 57. Heyderman E, Dagg B. p53 Immunostaining in benign breast disease. Lancet. 1991; 338: 1532-1532.
58. 58. Yamamoto M, Takahashi H. Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Arch A Pathol Anat. 1993; 422: 127-132.
59. 59. Dei Tos AP, Doglioni C, Laurino L, Barbareschi M, Fletcher CD. p53 Protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology. 1993; 22: 45-50.
60. 60. Ro YS, Cooper PN, Lee JA, et al. p53 Protein expression in benign and malignant skin tumors. Br J Dermatol. 1993; 128: 237-241.
61. 61. Shea CR, McNutt NS, Volkenandt M, Lugo J, Prioleau PG, Albino AP. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol. 1992; 141: 25-29.
62. 62. McNutt NS, Volkenandt M, Shea CR, Lugo J, Prioleau PG, Albino AP. Expression of p53 protein and statin in normal skin, actinic keratoses, and basal cell carcinomas. J Cutan Pathol. 1991; 18: 380; 18:380.
63. 63. McNutt NS, Shea CR, Volkenandt M, Lugo J, Prioleau PG, Albino AP. p53 Protein expression is frequent in basal cell carcinomas. Lab Invest. 1992; 66: 33a. Abstract.
64. 64. Moles JP, Theillet C, Basset-Seguin N, Guilhou JJ. Mutation of the tumor suppressor gene Tp53 is not detected in psoriatic skin. J Invest Dermatol. 1993; 101: 100-102.
65. 65. Tadini G, Cerri A, Crosti L, Cattoretti G, Berti E. p53 and oncogene expression in psoriasis. Acta Derm Venereol. 1989; 146(suppl): 33-35.
66. 66. Sim CS, Slater S, McKee PH. Mutant p53 expression in solar keratosis: an immunohistochemical study. J Cutan Pathol. 1992; 19: 302-308.
67. 67. Nagano T, Ueda M, Ichihashi M. Expression of p53 protein is an early event in ultraviolet light-induced cutaneous squamous cell carcinogenesis. Arch Dermatol. 1993; 129: 1157-1161.
68. 68. Wang E. Statin, a nonproliferation-specific protein, is associated with the nuclear envelope and is heterogeneously distributed in cells leaving quiescent state. J Cell Physiol. 1989; 140: 418-426.
69. 69. Connoly JA, Sarabia VE, Kelvin DJ, Wang E. The disappearance of a cyclin-like protein and the appearance of statin is correlated with the onset of differentiation during myogenesis in vitro. Exp Cell Res. 1988; 174: 461-471.
70. 70. Lee MJ, Sandig M, Wang E. Statin, a nuclear protein specific for non-proliferating cells, is a phosphoprotein and forms an in vivo complex with a p45 serine/threonine kinase. J Cell Biol. 1991; 115: 15: 18a. Abstract.
71. 71. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 1984; 4: 1689-1694.
72. 72. Campbell C, Quinn AG, Angus B, Farr PM, Rees JL. Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res. 1993; 53: 2697-2699.
73. 73. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A. 1992; 89: 4495-4499.
74. 74. Eeles RA, Warren W, Knee G, et al. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene. 1993; 8: 1269-1276.
75. 75. McGregor JM, Yu CCW, Dublin EA, Levison DA, MacDonald DM. Aberrant expression of p53 tumoursuppressor protein in non-melanoma skin cancer. Br J Dermatol. 1992; 127: 463-469.
76. 76. Sim CS, Slater SD, McKee PH. Mutant p53 protein is expressed in Bowen's disease. Am J Dermatopathol. 1992; 14: 195-199.
77. 77. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991; 88: 10124-10128.
78. 78. Moles JP, Moyyret C, Guillot B, et al. p53 Gene mutations in human epithelial skin cancers. Oncogene. 1993; 8: 583-588.
79. 79. Campbell C, Quinn AG, Ro YS, Angus B, Rees JL. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol. 1993; 100: 746-748.
80. 80. Barbareschi M, Girlando S, Cristofolini P, Cristofolini M, Togni R, Boi S. p53 Protein expression in basal cell carcinomas. Histopathology. 1992; 21: 579-581.
81. 81. Rady P, Scinicariello F, Wagner RF, Tyring SK. p53 Mutations in basal cell carcinomas. Cancer Res. 1992; 52: 3804-3806.
82. 82. Hanle S, Wienecke R, Konz B, Volkenandt M. Loss of heterozygosity of the p53 tumor suppressor gene is a rare event in basal cell carcinoma. Arch Dermatol Res. In press.
83. 83. Wienecke R, Eckert F, Kaudewitz P, De Viragh PA, Heidi G, Volkenandt M. p53 Protein in benign and malignant sweat gland tumors. Am J Dermatopathol. In press.
84. 84. Chen YT, Old LJ. p53 Gene alterations in human melanoma cell lines: implications on carcinogenesis. Lab Invest. 1992; 66: 31a. Abstract.
85. 85. Cristofolini M, Boi S, Girlando S, et al. p53 Protein expression in nevi and melanomas. Arch Dermatol. 1993; 129: 739-743.
86. 86. Otsuka F, Shima A, Ishibashi Y. Porokeratosis as a premalignant condition of the skin: cytologic demonstration of abnormal DNA ploidy in cells of the epidermis. Cancer. 1989; 63: 891-896.
87. 87. Ogden GR, Lane DP, Chisholm DM. p53 Expression in dyskeratosis congenita: a marker for oral premalignancy. J Clin Pathol. 1993; 46: 169-170.
88. 88. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993; 15: 332-342.
89. 89. Hopfl RM, Schir MM, Fritsch PO. Keratoacanthomas: human papillomavirus associated. Arch Dermatol. 1992; 128: 563-564.
90. 90. Gassenmaier A, Pfister H, Hornstein OP. Human papillomavirus 25-related DNA in solitary keratoacanthoma. Arch Dermatol Res. 1986; 279: 73-76.
91. 91. Wagner RF Jr, Cottel WI, Smoller BR, Kwan TH. Perineural invasion associated with recurrent sporadic multiple self-healing squamous carcinomas. Arch Dermatol. 1987; 123: 1275-1276.
92. 92. Washington CV Jr, Mikhail GR. Eruptive keratoacanthoma en plaque in an immunosuppressed patient. J Dermatol Surg Oncol. 1987; 13: 1357-1360.
93. 93. Geary WA, Cooper PH. Proliferating cell nuclear antigen (PCNA) in common epidermal lesions. J Cutan Pathol. 1992; 19: 458-468.
94. 94. Calonje E, Wilson Jones E. Intravascular spread of keratoacanthoma: an alarming but benign phenomenon. Am J Dermatopathol. 1992; 14: 414-417.
95. 95. Stephenson TJ, Royds J, Silcocks PB, Bleehen SS. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol. 1992; 127: 566-570.
96. 96. Albino AP, Vidal M, McNutt NS, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. In press.